SkinAware logo SkinAware
Contact Get updates

From awareness to action

Earlier skin cancer awareness, powered by AI.

A smartphone-based tool to support early skin cancer recognition and referral.

Why this matters

Skin cancer is common, but access is uneven.

  • Dermatology capacity is limited in many regions, creating delays in evaluation and referral
  • Primary care access is shrinking. An estimated ~100 million people in the U.S. lack reliable access to primary care, pushing concerns into urgent care, telehealth, or delayed presentation
  • Earlier recognition improves referral prioritization and helps focus specialist care where it is most needed

What makes SkinAware different

Many options are not validated, require hardware, or do not fit real care pathways. SkinAware is built for clinically credible triage and follow-through.

Accessible
Smartphone-first workflow
Clinically led
Designed for real-world use
Deployment-ready
Built for low-access settings

Founder story

Why SkinAware exists, and why the product is built around real access constraints.

Too many patients with potentially deadly skin lesions wait months for dermatology skin checks. In low access settings, clinicians are often asked to make calls outside their specialty. That creates risk, delays, and avoidable anxiety. I realized the two ingredients for a better pathway were already in everyone’s pocket: modern smartphone cameras and AI trained on large clinical image datasets. SkinAware is built to turn uncertainty into a clear next step, with sensitivity first triage and an emphasis on follow through. This is not about convenience. It is about equity, urgency, and reducing preventable harm when access is the bottleneck.
Kevin Phelan, MD, FACS • Founder and CEO

How it works

A simple workflow from photo to action. Built to integrate into real care pathways.

1

Image analysis

Take a clear photo with your phone. SkinAware analyzes the image using an ensemble model architecture.

2

Risk stratification

Results are presented as next-step guidance, designed for sensitivity-first triage.

3

Referrals and follow-through

Users can share results with a clinician and access vetted referral options where available.

4

Lesion tracking

Save photos over time to support monitoring and follow-up conversations with clinicians.

Analyzing a lesion photo in the SkinAware app
Image analysis
Routine evaluation recommended result screen
Routine evaluation recommended
Prompt evaluation recommended result screen
Prompt evaluation recommended
Lesion tracking list in the SkinAware app
Lesion tracking
Patent pending. USPTO Application No. 63/920,476.
Talk to us

Who it is for

A clear workflow story for clinicians, pilot partners, and the teams evaluating impact.

Patients and individuals

People who want faster clarity and a practical next step when access is limited.

  • Smartphone-only experience
  • Clear next-step guidance
  • Longitudinal photo tracking

Researchers and clinicians

Partners interested in validation, subgroup performance, and pathway impact.

  • Planned prospective validation
  • Fairness and subgroup measurement
  • Workflow integration and outcomes

Investors and accelerators

A scalable access solution with strong unit economics potential and mission alignment.

  • Large addressable market
  • Clear deployment wedge (low access)
  • Distribution via partners and pilots

Partner pathways

Pick the most relevant track. We respond quickly and keep it simple.

Pilot partners

  • Primary care, urgent care, telehealth, and rural clinics
  • Simple onboarding and lightweight workflow integration
  • Outcomes focus: triage quality, referrals, and time-to-next-step
Request pilot access →

Research collaborators

  • Dataset partnerships, evaluation design, and external validation
  • Shared learnings on performance by lesion type and patient context
  • Publication-ready methodology and documentation
Discuss collaboration →

Investors

  • Pre-raise relationship building and diligence materials
  • Clear milestones: pilots, validation, and deployment readiness
  • Mission-aligned approach to access and early detection
Request materials →

Initial benchmark snapshot

Internal benchmark on 217,000+ clinical images with smartphone-like capture characteristics. Results shown are a snapshot to inform pilots and diligence.

92%
Sensitivity
80%
Specificity
217k+
Clinical images
All tones
Fitzpatrick coverage evaluated

Context: These metrics reflect an internal benchmark and are provided for transparency. They are not clinical trial results and are not intended as diagnostic claims. We can share the evaluation approach and split details with qualified partners.

What we have built

A practical product foundation aimed at pilot readiness: capture, analysis, and next-step guidance.

Working product workflow

  • Smartphone-first lesion capture with guided framing
  • Fast analysis and clear risk categories
  • Next-step prompts designed for triage and referrals

Evaluation mindset

  • Internal benchmarking against large clinical image sets
  • Focus on sensitivity-forward triage behavior
  • Plans for external validation with pilot partners

Partnership focus

  • Built for primary care, telehealth, and rural access constraints
  • Low overhead onboarding and lightweight integration
  • Outcome tracking aligned to real clinical bottlenecks

Clinically led, execution focused

A team with experience in melanoma care, public health, and AI product development.

Kyisin Aung, MPH
COO
Public health leader. Multi-site workflow experience. Leads clinical partnerships and Foundation.
Kevin Phelan, MD, FACS
CEO
Surgeon and combat veteran. Leads clinical and regulatory strategy.
Nick Lind, MBA
Lead Engineer
Machine learning and data science. Leads development and model work.
Image analysis
Routine evaluation recommended
Prompt evaluation recommended
Lesion tracking
Interested in advising, piloting, or partnering? We are building a pathway from awareness to action for underserved and low-access communities.
Reach out

FAQ

Clear answers to reduce confusion and manage expectations.

Is SkinAware a diagnostic tool?

No. SkinAware provides analysis to assist with rapid risk assessment and next-step guidance. It does not diagnose or treat any medical condition.

What should a user do if they are worried?

Seek evaluation by a qualified healthcare professional. If there is bleeding, rapid change, or other concerning symptoms, do not wait for an app result.

How do you handle fairness across skin tones?

Internal benchmarks include all Fitzpatrick skin tones in the test dataset. Ongoing validation is planned to measure and improve subgroup performance.

What is the regulatory plan?

SkinAware is built as a sensitivity-first triage and referral tool. We plan staged validation and a longer-term FDA path aligned with intended use and claims.

How can researchers collaborate?

Use the contact form below. We are seeking partners for prospective validation, subgroup performance analysis, and pathway outcome studies.

Contact

For pilots, partnerships, research collaborations, or investor materials.

Email

founder@skinawarehealth.com

Foundation

skinawarefoundation.org

Company

skinawarehealth.com

By submitting, you consent to be contacted. Do not include protected health information.